T20, Enfuvirtide – 1 mg

Overview

T20, Enfuvirtide is a powerful synthetic peptide designed for the inhibition of HIV-1 viral fusion with CD4 cells. With an EC50 value of just 1 ng/ml, this 36-residue peptide mimetic effectively blocks crucial structural rearrangements of the gp41 component of the viral envelope glycoprotein. By precisely targeting the transitional pre-fusion conformation of gp41, T20 plays a critical role in antiviral research and therapeutic applications. For researchers looking to diversify their studies, consider exploring our range of peptides that can complement your work.

Key Features

• Strongly inhibits HIV-1 viral fusion.
• EC50 of 1 ng/ml for effective inhibition.
• 36-residue synthetic peptide mimetic.
• Blocks gp41 structural rearrangements at transitional pre-fusion conformation.
• Essential for HIV-1 research and analysis.

Specifications

FAQ

What is T20, Enfuvirtide used for?

T20, Enfuvirtide is primarily used in research to study HIV-1 viral fusion processes and to develop antiviral therapies. Its ability to inhibit fusion with CD4 cells makes it a valuable tool in understanding HIV mechanisms.

How is T20 administered in experiments?

T20 is typically administered in vitro, using cell cultures infected with HIV-1. Researchers assess its efficacy by measuring the reduction of viral fusion and replication within these cultures.

Can T20 be used in combination with other peptides?

Yes, T20 can be effectively used alongside other peptides to enhance research outcomes. For example, combining it with our Autocamtide-2 can provide deeper insights into peptide interactions in your studies.

For anyone interested in the intricate processes of HIV-1 treatment and research, T20, Enfuvirtide is a crucial addition to your laboratory. Shop now to equip your research with this essential peptide.

Related Products

• PKG Substrate [RKRSRAE], Glasstide
• CREBtide [KRREILSRRPSYR], 5-FAM labeled